XML 48 R27.htm IDEA: XBRL DOCUMENT v3.25.1
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS (Tables)
 3 Months Ended
Mar. 31, 2025
Accounting Policies [Abstract]  
Schedule of Research and Development
The following table represents the significant segment expenses regularly provided to the CEO:
Three Months Ended March 31,
Dollars in millions20252024
Research(a)
$314 $384 
Drug Development(b)
1,081 1,083 
Other(c)
861 1,228 
Research and development
$2,257 $2,695 
(a)    Includes costs to support the discovery and development of new molecular entities through pre-clinical studies.
(b)    Includes costs to support clinical development of potential new products, including expansion of indications for existing products through Phase I, Phase II and Phase III clinical studies.
(c)    Includes costs to support manufacturing development of pre-approved products, medical support of marketed products, acquisition-related charges and proportionate allocations of enterprise-wide costs including facilities, information technology, and other appropriate costs.